Skip to content
BY-NC-ND 3.0 license Open Access Published by De Gruyter Open Access October 24, 2006

Simultaneous treatment with carbimazole and granulocyte-colony stimulating factor in a patient with thyrotoxicosis and carbimazole induced neutropenia

Indrajit Talapatra, Vengal Nagareddy, Manju Bhavnani and David Tymms
From the journal Open Medicine

Abstract

We describe a patient who was admitted with uncontrolled thyrotoxicosis and carbimazole induced neutropenia. She required 80 mg of carbimazole daily. The patient declined radio-iodine treatment because she had a little child and wished to have thyroid surgery. She received four doses of filgrastim (Granulocyte-colony stimulating factor) which maintained the neutrophil count within a reasonable level while she continued to receive carbimazole to prepare her for surgery. After a curative subtotal thyroidectomy and discontinuation of the carbimazole, the patient’s white cell count remained normal. Subsequently the patient was euthyroid on levothyroxine replacement. Carbimazole should always be discontinued if neutropenia occurs but this case demonstrates that in exceptional circumstances filgrastim can be an effective therapy while continuing carbimazole in the short term.

[1] N. Biswas, A. You-hern, J.M. Goldman and J.M. Schwartz: “Case report: aplastic anemia associated with antithyroid drugs”, Am. J. Med. Sci., Vol. 301, (1991), pp. 190–194 http://dx.doi.org/10.1097/00000441-199103000-0000810.1097/00000441-199103000-00008Search in Google Scholar PubMed

[2] G. Birchell and T. Cheetham: “Juvenile thyrotoxicosis; can we do better?”, Arch. Dis. Child., Vol. 89(8), (2004), pp. 745–750 Search in Google Scholar

[3] U. Srinivas, S. Stanaway, R. Worth and D. Ewins: “Delayed carbimazole induced agranulocytosis precipitating thyroid crisis”, Endocrine abstracts, Vol. 5, (2003), P27. Search in Google Scholar

[4] F. Joseph, N. Younis and D. Bowen Jones: “Treatment of carbimazole-induced agranulocytosis and sepsis with granulocyte colony stimulating factor”, Int. J. Clin. Prac., Vol. 57(2), (2003), pp.145–146 Search in Google Scholar

[5] G. Wilcox, R. Wong, P.J. Elliott, D.J. Topliss and J.R. Sockigt: “Recovery from Carbimazole-Induced Aplastic Anaemia”, Int. J. Endocrinol. Metab., Vol. 1, (2003), pp. 41–43 Search in Google Scholar

[6] D. Usha, D.M. Thatte and S.A. Dahanukar: “Therapeutic potential of the haematopoietic growth factors”, J. Postgrad. Med., Vol. 40(4), (1994), pp. 210–15 Search in Google Scholar

[7] A. Oyama, K. Ota, S. Asano, F. Takaku, T. Miyazaki, Y. Uzuka, M. Omine, S. Furusawa, K. Hirashima, K. Sanpi et al: “Clinical effect of recombinant human G-CSF on neutropenia induced by chemotherapy for Non Hodgkin’s lymphoma”, Nippon Gan. Chiryo. Gakkai. Shi., Vol. 25(8), (1990), pp. 1619–1634. Search in Google Scholar

Published Online: 2006-10-24
Published in Print: 2006-12-1

© 2006 Versita Warsaw

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Scroll Up Arrow